The Enterprise Value as of November 2024 (TTM) for BioCryst Pharmaceuticals, Inc. (BCRX) is 2.29B

According to BioCryst Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 2.29B. This represents a change of 12.08% compared to the average of 2.04B of the last 4 quarters.

BioCryst Pharmaceuticals, Inc. (BCRX) Historical Enterprise Value (quarterly & annually)

How has BCRX Enterprise Value performed in the past?

The mean historical Enterprise Value of BioCryst Pharmaceuticals, Inc. over the last ten years is 1.18B. The current 2.29B Enterprise Value has changed 19.23% with respect to the historical average. Over the past ten years (40 quarters), BCRX's Enterprise Value was at its highest in in the March 2022 quarter at 3.22B. The Enterprise Value was at its lowest in in the March 2016 quarter at 225.81M.

BioCryst Pharmaceuticals, Inc. (BCRX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of BioCryst Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

BioCryst Pharmaceuticals, Inc. (BCRX) Average Enterprise Value

How has BCRX Enterprise Value performed in the past?

The current Enterprise Value of BioCryst Pharmaceuticals, Inc. (BCRX) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

BioCryst Pharmaceuticals, Inc. (BCRX) Enterprise Value vs. Peers

How is BCRX’s Enterprise Value compared to its peers?

BioCryst Pharmaceuticals, Inc.’s Enterprise Value is less than TG Therapeutics, Inc. (5.52B), less than Axsome Therapeutics, Inc. (4.65B), greater than Intercept Pharmaceuticals, Inc. (915.81M), greater than Seres Therapeutics, Inc. (158.02M), less than Madrigal Pharmaceuticals, Inc. (7.46B), greater than Kezar Life Sciences, Inc. (36.78M), greater than Immunic, Inc. (40.91M), greater than Atara Biotherapeutics, Inc. (54.85M), greater than Pieris Pharmaceuticals, Inc. (2.78M), less than Apellis Pharmaceuticals, Inc. (3.90B), less than Blueprint Medicines Corporation (6.36B), less than Karuna Therapeutics, Inc. (12.43B), less than Mirati Therapeutics, Inc. (3.91B), greater than Day One Biopharmaceuticals, Inc. (963.46M), greater than Anavex Life Sciences Corp. (633.73M), greater than Cassava Sciences, Inc. (1.12B), greater than INmune Bio, Inc. (77.34M), greater than BioVie Inc. (34.57M), greater than Cognition Therapeutics, Inc. (-3660923.00), less than Viking Therapeutics, Inc. (5.81B), greater than X4 Pharmaceuticals, Inc. (38.44M), greater than PDS Biotechnology Corporation (53.10M),

Build a custom stock screener for BioCryst Pharmaceuticals, Inc. (BCRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BioCryst Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

BioCryst Pharmaceuticals, Inc. (BCRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like BioCryst Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.